The past few decades have seen a marked change in the composition of commonly smoked cannabis. These changes primarily involve an increase of the psychoactive compound Δ 9 -tetrahydrocannabinol (THC) and a decrease of the potentially therapeutic compound cannabidiol (CBD). This altered composition of cannabis may be linked to persistent neuroanatomic alterations typically seen in regular cannabis users. In this review, we summarize recent findings from human structural neuroimaging investigations. We examine whether neuroanatomic alterations are 1) consistently observed in samples of regular cannabis users, particularly in cannabinoid receptor-high areas, which are vulnerable to the effects of high circulating levels of THC, and 2) associated either with greater levels of cannabis use (e.g., higher dosage, longer duration, and earlier age of onset) or with distinct cannabinoid compounds (i.e., THC and CBD). Across the 31 studies selected for inclusion in this review, neuroanatomic alterations emerged across regions that are high in cannabinoid receptors (i.e., hippocampus, prefrontal cortex, amygdala, cerebellum). Greater dose and earlier age of onset were associated with these alterations. Preliminary evidence shows that THC exacerbates, whereas CBD protects from, such harmful effects. Methodologic differences in the quantification of levels of cannabis use prevent accurate assessment of cannabis exposure and direct comparison of findings across studies. Consequently, the field lacks large "consortium-style" data sets that can be used to develop reliable neurobiological models of cannabis-related harm, recovery, and protection. To move the field forward, we encourage a coordinated approach and suggest the urgent development of consensus-based guidelines to accurately and comprehensively quantify cannabis use and exposure in human studies.
tetrahydrocannabinol (THC) (2) , which exerts persistent adverse effects on cognition, mental health, and the brain (3, 4) . In parallel, there are decreasing levels of other constituent cannabis compounds, such as cannabidiol (CBD), which has been touted as a potential therapeutic agent for conditions ranging from chronic pain and seizures to psychiatric symptoms (5-7). These recent changes in the composition of "street" cannabis create a new and complex landscape for investigators endeavoring to understand the neurobiological harm and the therapeutic potential of cannabis products.
Specific cannabinoid compounds have distinct effects on mental health and brain function. The psychoactive and addictive properties of cannabis are primarily due to THC (8) . Increased availability of cannabis varieties that are high in THC (e.g., "skunk") have been consistently linked to accelerated onset of psychosis (9, 10) , increased cannabis-related hospital admissions (11) , and increased anxiety symptoms and psychotic-like experiences (12) (13) (14) (15) . Preclinical studies showed that THC is neurotoxic to brain areas rich in cannabinoid type 1 receptors, including the hippocampus (16) (17) (18) (19) (20) , amygdala (20) , striatum (21) , and prefrontal cortex (PFC) (21) (22) (23) . In contrast, CBD has been found to have anxiolytic, antipsychotic, and therapeutic properties (24) (25) (26) (27) . There is evidence suggesting that CBD is neuroprotective, mitigating the neurotoxic effects of THC (28) (29) (30) .
The compounds THC and CBD have also been shown to have opposing effects on the functional activity and connectivity between brain regions that are high in cannabinoid receptors, such as the hippocampus, amygdala, striatum, cerebellum, and PFC (12) (13) (14) (31) (32) (33) (34) (35) (36) . These changes in brain function, documented using functional magnetic resonance imaging (MRI), may modulate the effects of THC on anxiety and psychotic-like experiences in humans (5, 32, 37) . Similar processes may underpin the protective effects of CBD on such experiences (5, 6, 27, 32, 37) . Participants pretreated with CBD do not experience the psychotogenic and anxiogenic effects of THC (12) (13) (14) (32) (33) (34) (35) (36) (37) .
The recent changes in the relative composition of cannabinoids found within commonly available cannabis increase the potential for psychological and neurobiological harm in the current generation of cannabis users. However, the relative contribution of the two major compounds of cannabis (i.e., THC and CBD) to such damage is unclear (37) . In this review, we summarize the current literature on neuroanatomic alterations reported in regular cannabis users, which includes nine additional studies relative to the most recent review on the topic, reflecting an increased focus on this field of research and warranting a need to integrate the most recent findings (38) (39) (40) (41) (42) (43) (44) (45) (46) . We present a novel focus on the emerging evidence for differential roles of specific cannabinoids in neuroanatomic abnormalities (41, 43, 47, 48) . First, we provide an overview of findings and stratify them according to brain regions. Second, we examine the link between neuroanatomic alterations and levels of cannabis use, with a specific focus on the cannabinoid compounds THC and CBD. Finally, we identify major limitations of current research, particularly in relation to the measurement of cannabis use and cannabinoid compounds. These methodologic inadequacies limit the ability to develop evidence-based models of the effects of cannabis on neuroanatomy, whereby specific patterns (and types) of cannabis use are associated with discrete alterations in defined neural circuits. We suggest that a coordinated approach is required to move the field forward, and we offer preliminary guidelines to develop a standardized protocol to measure levels of cannabis use.
METHODS AND MATERIALS
We performed a PubMed search on April 7, 2015, using the keywords "Cannabis OR Marijuana" AND "MRI OR Computed Tomography OR Neuroimaging" and identified 492 articles. We screened these studies according to the following inclusion criteria: 1) use of structural neuroimaging techniques and 2) examination of regular cannabis users (as defined by each study protocol). We excluded nonempirical studies and samples including any other regular substance use or major psychopathologies. We included 32 studies in this review for further inspection (30, (38) (39) (40) (41) (42) (43) (44) (45) (46) , of which 23 were described previously (47) . Nine additional studies conducted since 2012 were identified (38) (39) (40) (41) (42) (43) (44) (45) (46) . The newest studies add to the literature five investigations of the PFC (38) (39) (40) (41) (42) 44) and of the hippocampus (39, 40, (44) (45) (46) ; four investigations of the amygdala (39, 41, 44, 46) ; three investigations of the striatum (39, 41, 43) ; two investigations of the insula (40, 41) ; and single investigations of the parietal and occipital cortices (41) , cerebellum (39) , and pituitary gland (38) .
RESULTS

Characteristics of Samples Included in Structural MRI Studies
Key characteristics of the reviewed samples are summarized in Table 1 and Figure 1 . The total sample sizes included between 15 and 30 participants [range, 8 (63) to 62 (42) control subjects and 10 (70) to 57 (65) cannabis users]. Mean ages of cannabis users were between 17 years (49,54) and 40 years (38, 45, 50, 58) . The age distribution varied within samples, ranging from 16 years (49,54) to 60 years (38, 45, 50, 58) .
All samples of cannabis users smoked cannabis regularly, on a daily (30, 39, 40, (42) (43) (44) 49, 51, 62, (68) (69) (70) or almost daily (38, 41, 45, 50, 53, 55, 58, 61, 63) basis. Some studies did not provide information on frequency of use but estimated the number of smoking episodes (52, 54, 56, 57, 60, 64) and joints (38, 45, 50, 58, 59, (65) (66) (67) . Most cannabis users started smoking between age 15 and 17 years. Participants in a few samples started smoking 1 or 2 years earlier [14 years (43, 52) ] or later [18-20 years (38,42,45,50,53,58,64) ]. Duration of use varied greatly across all examined samples and ranged from 2 years (54,60) to 23 years (62,69) of regular use. Lifetime exposure to cannabis was computed in cumulative number of joints, cones (standard cannabis unit, with 1 joint = 3 cones, 1 g = 12 cones; for other conversions, see guidelines from the National Cannabis Prevention and Information Centre at https://ncpic. org.au/media/1593/timeline-followback.pdf) (red triangles in Figure 2 ), or smoking episodes (blue squares in Figure 2 ), which was available for all but a few studies (39, 43, 64, 66, 67, 69, 70) .
Lifetime episodes of cannabis use ranged from 402 (60) to 5625 (42) . Lifetime cumulative cannabis dosage (dosage 3 smoking days 3 duration of regular use) ranged from 5322 cones (30) to 68,000 cones (68) . Most studies measured cannabinoid compounds, with three exceptions (39, 55, 62) . In 20 studies, urinalysis was used to detect cannabinoid compounds. Eight studies reported the levels of cannabinoid metabolites. Mean values for 11-nor-9-carboxy-THC (THC-COOH) (green circles in Figure 2 ) were reported from toxicology analyses of urine samples in eight studies (38, 40, 45, 49, 50, 54, 58) and analyses of hair samples in one study (30) . In 11 studies, positive [three studies (44, 53, 63, 64) ] or negative [eight studies (51, 56, 57, (59) (60) (61) 65) ] returns were reported from toxicologic analysis of urine samples without quantification.
The reviewed studies used various specimens to detect cannabinoids or their metabolites, including urine samples in 19 studies (30, 38, (40) (41) (42) (43) 45, 49, 50, 52, 54, (56) (57) (58) (59) (60) 63, 64, 71) , oral fluid (40) and blood samples (40) in single studies, and hair in 2 studies (30, 44) , only one of which reported the outcome of the assessment (30) ( Table 1) . Some studies used several specimens [i.e., hair and urine (30, 44) , blood and oral fluid (40) ]. Breathalyzers were used in five studies to screen for acute intoxication (52, 56, 57, 59, 60) . Several studies controlled for the confounding effects of alcohol (n = 18) and tobacco use (n = 13) ( Table 1 ) by covarying for their influence in group comparisons or reanalyzing the data after excluding participants with concurrent alcohol and tobacco use.
Neuroanatomic Alterations in Regular Cannabis Users Relative to Control Subjects
Neuroanatomic alterations were reported in several brain regions (Table 2 and Figure 3A ). Abnormalities in cannabis users, relative to control subjects, emerged most consistently in the hippocampus [seven studies (30, 40, 45, 51, 58, 63) ]. Several studies reported alterations in the volume (i.e., sum of all voxels that are included within the boundaries of the region of interest) and gray matter density (i.e., amounts of gray or white matter concentration in each voxel) within the amygdala and striatum (41, 43, 52, 58, 63) , PFC (40) (41) (42) 49, 55, 70) , parietal cortex (41, 49, 55) , insular cortex (40, 41, 49) , and cerebellum (50, 53, 56) . Single studies reported alterations within the fusiform gyrus (63) , temporal pole, superior temporal gyrus, and occipital cortex (41). 
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Values for all measures are mean (SD). abst., abstinence; AUDIT, Acohol Use Disorder Identification Test; CB, cannabis users or cannabis; cig., cigarettes; cone, standardized cannabis unit; cov., covariate; ep., episodes; excl. users, excluded users with comorbid alcohol or tobacco use (or both); FTND, Fagerström Test for Nicotine Dependence scores; HC, healthy non-cannabis using control subjects; life., lifetime; occ., occasional use; past 1 year, over the past 12 months; R, range; reg., regular cannabis use; regr., regressor; SD, standard deviation; THC, Δ Overall, neuroanatomical alterations included most consistently 1) volumetric reductions in all regions, with the exception of the cerebellum and striatum, where larger volumes were also observed (41,50,53); 2) higher gray matter density in most regions (amygdala, PFC, parietal cortex, striatum), with the exception of one study that found lower prefrontal gray matter density in cannabis users relative to control subjects (41)-this exception may result from noise or reflect a true change demonstrating complex effects of cannabis on gray matter density; 3) altered shape, sulcal-gyral anatomy; and 4) cortical thickness (49) . There is substantial overlap between the location of the neuroanatomic alterations in cannabis users (blue heat map, Figure 3A ) and the location of high-density concentration of cannabinoid type 1 receptors (green heat map, Figure 3B ) (31) .
Most studies found abnormalities within the hippocampus, which has a very high cannabinoid receptor density relative to other brain regions [i.e., 1680 binding sites across all hippocampal subregions (31) ]. Neuroanatomic abnormalities also were found in prefrontal regions with very high densities of cannabinoid receptors [i.e., 627 and 518 binding sites within the lateral PFC and anterior cingulate cortex, respectively (31)]. Also, the amygdala and cerebellum, brain regions that show consistent abnormalities, have a high density of cannabinoid receptors [i.e., 102 and 137 binding sites, respectively (31) ]. There appears to be an intriguing link between the concentration of cannabinoid receptor density in the brain and the consistency with which studies detect abnormal neuroanatomy in regular cannabis users.
Associations With Levels of Cannabis Use
The link between neuroanatomy and cannabis use levels was examined in 21 studies (Figure 4) (30,38-42,44,45,49-55, 57,58,62-65) . Cannabis dosage was most consistently associated with the neuroanatomy of the hippocampus (30, 51, 53, 58) and PFC (44, 49, 57) and less consistently with the neuroanatomy of the amygdala, striatum (41), parahippocampal gyrus, insula, and temporal pole (40) . Age of onset was most consistently associated with prefrontal neuroanatomy (49, 54) and less consistently with the neuroanatomy of the parahippocampal gyrus, temporal cortex (40) , and global brain measures (49) . Duration of regular use was associated with the neuroanatomy of the PFC (57) and hippocampus (63) but not with the neuroanatomy of the amygdala (51), parahippocampal gyrus (40, 44, 63) , cerebellum (44, 52) , and striatum (41) . Most studies did not examine the association between cannabis use measures and neuroanatomy (Figure 4 ).
Associations Between Quantified Cannabinoid Levels and Neuroanatomy
Five studies examined the link between quantified cannabinoid levels and the neuroanatomy of the hippocampus (30, 45, 58) , PFC (38, 49) , and amygdala (58) as well as the cerebellum in a sixth additional study [cited by Lorenzetti et al. (48) ]. Four studies found significant associations (30, 49) . Demirakca et al. (30) found a significant association between higher ratio of THC/CBD (but not THC, measured as ng/mg hair, mean .31 ng/mg, SD .2 ng/mg) and smaller right hippocampal volumes and bilateral hippocampal gray matter concentration. A similar finding was reported in a separate sample of cannabis users with reduced hippocampal volume relative to controls (72); a subgroup of users with high levels of THC (and no detectable levels of CBD) in hair showed more marked reductions relative to control subjects than the other users, who had detectable levels of THC and CBD (72) . Two studies examined the association between prefrontal neuroanatomy and urinary THC metabolite levels (38, 49) , with one finding being a significant association between higher levels of THC-COOH (mean 455 mg/mL, SD 352 mg/mL) and the thickness of prefrontal (and parietal) cortices (49) . In light of findings suggesting a role for THC metabolites in neuroanatomic alterations, N. Solowij, Ph.D., et al. (personal communication, April 2015) re-examined a data set on cerebellar neuroanatomy (50) . They found that higher levels of THC-COOH in urine measured the night before (Spearman ρ 5 2.577, p 5 .049) and on the day of the MRI scan (Spearman ρ 5 2.790, p 5 .002) ( Figure 5 , left plot) were associated with reduced cerebellar gray matter in cannabis users. The latter relationship was strengthened with the removal of three cannabis users with very high levels of urinary cannabinoid metabolites (Spearman ρ 5 2.87, p 5 .002) ( Figure 5, right plot) .
Only one study examined the link between CBD and neuroanatomy in cannabis users (30) . The CBD levels (ng/mg hair, mean .13 ng/mg, SD .12 ng/mg) were associated with higher hippocampal gray matter concentration (but not volume). Similarly, we recently found that cannabis users with high levels of CBD showed no hippocampal volume abnormalities [i.e., were comparable to control subjects (72) ]. In contrast, the whole group of cannabis users, particularly users with high THC and no detectable levels of CBD, showed significant hippocampal reductions relative to control subjects (72) .
DISCUSSION
The reviewed literature demonstrates that regular exposure to cannabis is associated with neuroanatomic alterations in several brain regions, most consistently within the hippocampus (reduced volumes and gray matter density, altered shape), followed by the amygdala and striatum, orbitofrontal 
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Biological Psychiatry April 1, 2016; 79:e17-e31 www.sobp.org/journal cortex, parietal cortex, insular cortex, and cerebellum. Some associations emerged between higher cannabis dosage and hippocampal alterations and between earlier age of onset and PFC alterations. These trends (i.e., hippocampal volumetric reduction) were previously observed (47), although there is now increasing evidence for alteration within other regions (i.e., striatum, orbitofrontal cortx, parietal cortex, insular cortex, cerebellum). There was also preliminary evidence that neuroanatomic alterations within the hippocampus, cerebellum, prefrontal, and lingual regions were associated with THC and CBD levels specifically, suggestive of an adverse effect of THC and a protective effect of CBD (from THC-related damage). Neuroanatomic abnormalities were most reliably found in regions that have a high concentration of cannabinoid type 1 receptors, to which THC binds to exert its psychoactive effects (31) . Cannabis plants that are typically used for drug production have high levels of THC (17%-20%) (73) but low levels of CBD (1). According to preclinical findings, THC accumulates in neurons (74) and with chronic exposure becomes neurotoxic (18) . Neuroanatomic abnormalities may result from the adverse effects of direct and chronic exposure to high levels of THC found in commonly available "street" cannabis. Although CBD may be neuroprotective (24, 25) and mitigate the adverse effects of THC (47, 85) , it is seldom found in high levels (1) . As one of the regions of highest density of cannabinoid type 1 receptors (3), damage to the hippocampus may be related to THC-induced neurotoxicity.
Putative Mechanisms
Neuroanatomic alterations in areas that are high or low in cannabinoid receptors may result from distinct mechanisms. Alterations within regions high in cannabinoid type 1 receptors (hippocampus, amygdala, cerebellum, anterior cingulate cortex) may involve 1) accumulation of THC and its metabolites in neurons (74) that leads to THC-induced neurotoxicity [e.g., shrinkage of neuronal cell nuclei and bodies (19, 20) , reduced synapse number (20) , and reduced pyramidal cell density (16, 76) ]; 2) downregulation, adaptation, and molecular and signaling changes downstream of cannabinoid receptors (77) (78) (79) (80) (81) (82) ; and 3) changes in vascularity, and reductions in glia and neuronal dendrites, which are associated with gray matter volumes (83) (84) (85) .
Chronic cannabinoid-induced alterations of neural oscillations in cannabinoid receptor-high regions [i.e., shown in preclinical studies of the hippocampus (86, 87) and amygdala (88, 89) ] may propagate (90) to functionally and structurally connected cannabinoid receptor-low regions [e.g., parietal cortex (91-93) and orbitofrontal cortex (94) ] and lead to neuroanatomic alterations of the latter. Previous studies in neurodegenerative disorders showed a direct link between alteration of connectivity (i.e., synchrony of activity) between functionally and structurally related regions and alteration of gray matter volumes in the same areas (95) . Cannabis users show impaired functional (34, 96) and structural (97) connectivity between cannabinoid receptor-high regions (i.e., hippocampus) and cannabinoid receptor-low regions (i.e., parietal cortex, inferior frontal gyrus). In this review, cannabis users showed neuroanatomic alterations in both regions. These regions are integral components of the brain reward (98), memory (99) , and executive-attention systems (100,101) and may mediate the deficits that cannabis users show in these domains (93, 98, (99) (100) (101) (102) (103) (104) . The compound CBD may counteract THC-induced damage to neuroanatomy, as it has been shown to alleviate neurodegeneration, reverse brain ischemic damage in mice (24) , and modulate the effects of THC by blocking cannabinoid type 1 receptors (105-107). The molecular mechanisms by which CBD counteracts the effects of THC are unclear (24, 105) . It may be that CBD, via attenuating THC-induced effects on brain function (13, 14, 34, 36) , prevents the onset of molecular mechanisms that would trigger neurotoxicity and lead to neuroanatomic abnormalities in cannabis users. Multimodal imaging studies in cannabis users that carefully examine levels of THC and CBD (prior proportional exposure from hair analysis and circulating levels in urine, blood, and oral fluid samples) would help elucidate the potential neurotoxic, neuroadaptive, or neuroprotective mechanisms involving different cannabinoids.
Limitations of Reviewed Literature
There are major gaps in the measurement of cannabinoids and cannabis use levels [e.g., dose, duration, frequency, age of onset (47, 75, 108) ]. The development of standardized methods to characterize cannabis users and to identify the effects of specific cannabinoids on the brain is warranted.
Measurement of Cannabinoid Levels. Hypotheses and interpretation concerning neuroanatomic alterations in cannabis users often postulate that THC drives these effects.
However, few studies have tested this model directly by obtaining quantified measures of THC-specific exposure. Quantifying cannabinoid levels in hair could provide levels of THC and CBD to which cannabis users have been exposed cumulatively over a few months (109, 110) . Also, metabolites in blood or urine measure circulating cannabinoids, which reflect exposure over recent hours, days, or weeks, and, in daily or near-daily users, indicate typically circulating levels. Although methods exist for quantifying cannabinoid exposure, such indices are underreported. The role of cannabinoid compounds in causally driving neuroanatomic alterations in cannabis users cannot be ascertained.
Improvements in the time frame and reliability of toxicology tests are warranted (111) . For example, hair analyses inform the past 3 months of exposure and rely on length of hair available (1 cm of hair 5 1 month of exposure), which most (but not all) participants can provide (109, 110) . We need better reliability and validity studies for toxicology analyses, as there is limited and contradictory evidence on this topic [e.g., urine toxicology tests may not match positive self-reports of cannabis use (111)]. Development of further measures of cannabinoid metabolites that enable more reliable detection of CBD in urine and other relevant cannabinoid metabolites that have longer time windows may help in the objective measurement of cannabinoid exposure. Finally, cannabinoid compounds from specimens collected from participants may not be stable over time (e.g., use of different varieties, breeds, or parts of the cannabis plant). Although it would be difficult to systematically control for this, assaying cannabinoid content from specimens, particularly in prospective studies, may inform future work on their neurobiological impact.
Underreporting Key Aspects of Cannabis Use. Key aspects of cannabis use are often not measured or reported, including the 1) type of cannabis predominantly used by the sample, the potency of which varies between marijuana [1%-20% THC (1)], hashish ( 10%), and hashish oils [up to 50% (112)]; 2) use of tobacco in cannabis preparations, which can almost double the release of THC compared with smoking pure cannabis (113); and 3) usual dosage and days of use, age of onset of regular use, and problems associated with use (114) . The underreporting of levels of exposure limits our understanding of the effects of cannabis use levels on the human brain.
Noisy Measurements. Measuring levels of cannabis use is an inherently difficult task. Self-reported levels of use are compromised by retrospective accounts including difficulties in remembering changes in use over the years, which are exacerbated by memory deficits in cannabis users (102, (115) (116) (117) . Studies measure differently levels of cannabis dosage (e.g., joints, smoking occasions, grams), frequency (e.g., smoking either occasions or days), and age of onset (e.g., of either first try or of regular use). Levels of use are estimated over distinct time windows (i.e., "usual" use; past 1-6 months, past 1 year, 10 years, lifetime), and duration and cumulative exposure measures often do not account for periods of prolonged abstinence. These issues prevent a direct comparison of findings across studies.
Lack of a Comprehensive Tool. No single instrument
captures all key aspects of exposure to cannabis use and cannabinoids (Table 3) . Research groups often develop their own in-house tools, which are not validated and standardized to perform accurate measurements of the history of use [e.g., periods of prolonged abstinence or of heavier use (50, 58) ]. The studies reviewed employed different instruments (114), obviating direct comparisons in the level of use across the reviewed samples. Methodologic issues in measuring cannabis use preclude the development of evidence-based neurobiological models of cannabis-related harm in humans, which rely on preclinical evidence (130, 131) that cannot be replicated in humans, given the interspecies differences in neuroanatomy (132) and different routes of administration in animal studies (i.e., oral, consistent doses) and human studies (i.e., inhaling cannabis smoke or vapors, variable doses), which create different models of metabolizing THC (76) . We propose the development of internationally agreed-on standards for quantifying exposure levels as a necessary step to develop evidence-based neurobiological models of cannabis use. The platform PhenX Toolkit previously took steps in this direction to improve the standard of research in substance use (133) . In this review, we incorporate these useful guidelines (i.e., lifetime/recent use, age of onset, diagnostic assessment for problem use) and include additional items that are specific to cannabis use research. Table 4 lists recommended criteria for assessing regular cannabis use as a starting point for further discussion and consensus around improving standardization of measurements within the international community of cannabis researchers. We acknowledge that it will prove difficult, if not impossible, to determine the exact amount of THC that cannabis users may be exposed to over significantly varying periods of time and drug availabilities. However, an attempt at a more standardized approach is necessary to isolate factors that may cause brain alterations.
CONCLUSIONS
Regular cannabis users show abnormalities within brain regions that are high in cannabinoid type 1 receptors, particularly the hippocampus and the PFC. These abnormalities are associated with higher levels of cannabis use (dosage, age of onset, duration). The psychoactive compound THC may be responsible for neuroanatomic damage in cannabis users, whereas the potentially therapeutic compound CBD may protect from such damage. Further evidence is needed to verify this hypothesis. To develop evidence-based neurobiological models of cannabis-related harm, objective measurement of cannabinoid compounds and the development of standardized measures of levels of cannabis use are necessary next steps. Objective measurements also need to keep up to date with the continually changing cannabinoid compounds (e.g., CP-55940, WIN) in increasingly available synthetic cannabinoids [e.g., K2, Spice (139)], which mimic the psychoactive effects of THC, causing significant mental health harm (140, 141) and unknown effects on the brain.
The mechanisms by which distinct cannabinoid compounds harm (and benefit) the brain are unclear. Research on the neurobiology of cannabinoids is not keeping up to date with ongoing public policy debates on the legalization as well as the therapeutic potential of the drug. To bridge this gap, we urgently need to develop standardized measurements of cannabis use levels and evidence-based neurobiological models of cannabinoid exposure.
